(Total Views: 465)
Posted On: 02/12/2021 10:58:53 PM
Post# of 154033
Probably not in the protocols
Seems reasonable that they will follow up LL treatment group to monitor, among other things, the incidence of long hauler syndrome.
That might be a nice % to broadcast, while in the middle of their own long hauler FDA trials, which hopefully will have great results too.
Similarly, for any of the LL treatment patients with comorbidities, couldn't they monitor any improvements, post treatment, for those specific comorbidities?
Considering the variety of reported CCR5 indications for LL, the thought occurred to me that this thought might've crossed their minds. Maybe too complicated, too much work and cost. Maybe.
Seems reasonable that they will follow up LL treatment group to monitor, among other things, the incidence of long hauler syndrome.
That might be a nice % to broadcast, while in the middle of their own long hauler FDA trials, which hopefully will have great results too.
Similarly, for any of the LL treatment patients with comorbidities, couldn't they monitor any improvements, post treatment, for those specific comorbidities?
Considering the variety of reported CCR5 indications for LL, the thought occurred to me that this thought might've crossed their minds. Maybe too complicated, too much work and cost. Maybe.
(1)
(0)
